SCHEMBL3083133

SCHEMBL3083133

Nc1ccc(-c2ccncc2)cc1C1=CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.48
CYP3A4 P08684 4/20 0.46
CSF1R P07333 3/20 0.46
CYP2C9 P11712 1/20 0.46
AAK1 Q2M2I8 1/20 0.44
CYP11B2 P19099 3/20 0.42
CYP17A1 P05093 1/20 0.42
CYP19A1 P11511 1/20 0.42
CYP11B1 P15538 1/20 0.42
HDAC1 Q13547 5/20 0.41
HDAC2 Q92769 5/20 0.41
HDAC3 O15379 2/20 0.40
PDPK1 O15530 1/20 0.37
PSMB5 P28074 1/20 0.36
PTGS2 P35354 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3096261 0.86 CSF1R (0.46) CYP3A4CSF1RHDAC1HDAC2HDAC3
SCHEMBL3096089 0.85 PTGS2 (0.43) CSF1RHDAC1HDAC2HDAC3PTGS2
SCHEMBL16387219 0.84 HDAC2 (0.52) HDAC1HDAC2HDAC3PTGS2
SCHEMBL13180457 0.84 HDAC1 (0.41) CYP3A4CSF1RCYP2C9HDAC1HDAC2
SCHEMBL3083333 0.83 CYP11B1 (0.50) CYP3A4CSF1RCYP2C9CYP11B2CYP17A1
SCHEMBL3088797 0.80 HDAC1 (0.39) CSF1RHDAC1HDAC2HDAC3PSMB5
SCHEMBL3086559 0.80 CSF1R (0.53) KDRCYP3A4CSF1RCYP2C9HDAC1
SCHEMBL3083131 0.80 CHUK (0.52) KDRCYP3A4CSF1RCYP2C9
SCHEMBL3089993 0.78 CSF1R (0.50) CSF1RHDAC1HDAC2HDAC3PTGS2
SCHEMBL15583348 0.77 PTGS2 (0.43) CSF1RHDAC1HDAC2HDAC3PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US claimed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP claimed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO claimed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US claimed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER KDR 70/4885CYP3A4 2812/4885CSF1R 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.